Generic Name and Formulations:
Bosutinib 100mg, 400mg, 500mg; tabs.
Indications for BOSULIF:
Newly-diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Take with food. Swallow whole. Continue until disease progression or patient intolerance. Newly-diagnosed: 400mg once daily. Renal impairment (CrCl 30–50mL/min): initially 300mg daily; (CrCl <30mL/min): initially 200mg daily. With resistance/intolerance to prior therapy: 500mg once daily. Renal impairment (CrCl 30–50mL/min): initially 400mg daily; (CrCl <30mL/min): initially 300mg daily. Both: hepatic impairment: initially 200mg daily. Dose escalation or dose adjustments for toxicity: see full labeling.
<18yrs: not established.
Monitor and manage GI toxicity, fluid retention; withhold, reduce dose, or discontinue as necessary. Perform CBC weekly for first month, then monthly; hepatic enzyme tests monthly for first 3 months (more frequently if transaminase elevations occur); withhold, reduce dose, or discontinue as necessary. Monitor renal function at baseline and during therapy; consider adjusting dose if renal impairment occurs. Dialysis: not studied. Embryo-fetal toxicity. Pregnancy; exclude status prior to initiation. Females of reproductive potential should use effective contraception during and for ≥1 month after last dose. Nursing mothers: not recommended (during and for ≥1 month after last dose).
Tyrosine kinase inhibitor.
Potentiated by concomitant strong or moderate CYP3A inhibitors (eg, ketoconazole, aprepitant, grapefruit products); avoid. Antagonized by concomitant strong or moderate CYP3A inducers (eg, rifampin, St. John’s wort); avoid. Antagonized by proton pump inhibitors (eg, lansoprazole); consider short-acting antacids or H2 blockers instead; separate dosing by ≥2hrs.
Diarrhea, nausea, thrombocytopenia, rash, vomiting, abdominal pain, anemia, pyrexia, abnormal LFTs, fatigue, cough, headache, edema; fluid retention, hepatic or renal toxicity.
Hepatic (CYP3A4); 94% protein bound.
Fecal (primary), renal.
Tabs 100mg—120; 400mg, 500mg—30
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Improving the Care of Aging Adults Living With HIV
- Infection Prevention Differs Between Small, Large Hospitals
- International Antiviral Society-USA Updates Recommendations for HIV Treatment and Prevention
- Previous Missed Appointments Predict Likelihood of Trend in Patients With HIV
- FDA Warns Against Long-Term Azithromycin Use for Some
- Identifying the Source of C difficile in Hospitalized Patients
- Antibiotics Often Unnecessary for Sacral Pressure Ulcers Complicated by Osteomyelitis
- Sensitivity and Specificity of 7 Treponemal Tests for Syphilis Diagnosis
- Automated EHR Algorithm More Effective Than Nurse-Driven Protocol for HCV, HIV Screening
- A Pan-Tuberculosis Regimen: The Debate Continues
- HCV Eradication in HIV/HCV-Coinfection Decreases Immune Activation
- Tolerability of Switching to Long-acting Cabotegravir Plus Rilpivirine From Current HIV-1 Regimen
- Time to Blood Culture Positivity Predictive of Mortality in S Aureus Infective Endocarditis
- C difficile Tied to Increased Graft Loss in Solid Organ Recipients
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd